(3) Exciting articles on breakthrough findings: AR-V7 and resistance to treatment with enzalutamide/ abiraterone, Denosumab therapy and risk for severe hypocalcemia and New form of experimental immunotherapy

 

 

Hi Guys,

Here are 3 articles that I find exciting about potential breakthrough findings dealing with prostate cancer patients.  Most patients like myself has tried or will be trying Zytiga or Xtandi for PSA control.  Article #1 states (39 percent) Among the men treated with enzalutamide had detectable AR-V7 in circulating tumor cells and Among the men treated with abiraterone acetate (19 percent) had detectable AR-V7 in circulating tumor cells.  Article# 2 states Denosumab, similar to Zometa  is associated with a rare but well-known risk for severe hypocalcemia.   Article #3 states a new form of prostate cancer immunotherapy test (ADXS-PSA) in combination  with an investigational drug called pembrolizumab

#1 AR-V7 and resistance to treatment with enzalutamide, abiraterone  Sept.4 2014

Early reports that prostate cancer patients carrying the androgen receptor subtype known as AR-V7 (the “isoform” encoded by splice variant 7) exhibit a high level of resistance to treatment with both enzalutamide (Xtandi) and abiraterone acetate (Zytiga). Full story: AR-V7 and resistance to treatment with enzalutamide,

 

#2 Denosumab — marketed as Xgeva and as Prolia — is associated with a rare but well-known risk for severe hypocalcemia (very low calcium in the blood stream).  Sept.3 2014

A recent case study reported by Muqeet Adnan et al. emphasizes the importance of patients having their serum levels of vitamin D and calcium checked prior to any initial administration of denosumab for the prevention of bone loss and other skeletal-related events.  Full Story: Denosumab therapy and risk for severe hypocalcemia

#3 New form of prostate cancer immunotherapy test (ADXS-PSA)  Aug. 25 2014

PD-1 inhibitors work by blocking the effects of a protein called PD-1 (formally known as the programmed cell death 1 protein), which normally controls the growth and release of immune system cells, thus making it easier for immune system cells to attack invading cancer cells.

Life is the death sentence, not the disease !

Craig Becker

The New Denver Men’s Club

Blog: https://newdenvermensclub.wordpress.com/ “Men Fighting Cancer To Win”

You can read all my posts at the blog site by clicking here
 

 

 

 

Advertisements

(2) potential breakthrough articles! ethinylestradiol for castration-resistant prostate cancer

 

Hi Guys,

Check out the promising results of this study with only 14 patients and the second article they call a major breakthrough!

ut-logo websitePublished on 18 July 2014

1)  Oral ethinylestradiol administration may have efficacy for CRPC without severe adverse events. Ethinylestradiol may be one of the selective drugs for CRPC patients who do not wish to undergo intravenous chemotherapy or become resistant to docetaxel.

“RESULTS: All patients had already been treated with a combined androgen blockade (CAB), 8 patients had been treated with docetaxel, 9 patients with tegafur-uracil, 4 patients with estramustine phosphate sodium. Age and prostate-specific antigen (PSA) at prescription of ethinylestradiol was 55-85 (median 75.5) and 0.784-508.7 ng/ml (median 4.842 ng/ml). Thirteen patients (92.9%) achieved a decline in PSA, 8 patients (57.1%) achieved a decline in PSA > 50%. Time to progression was 0-18 months (median 7 months), and there were no severe adverse events including venous thromboembolic diseases”.  Full Story: efficacy-of-ethinylestradiol-for-castration-resistant-prostate-cancer

2)  Structure of protein vital to cancer development is mapped   Monday 21 July 2014

A major breakthrough has been made by scientists who have successfully managed to map out the structure of a complicated protein that is regarded to be one of the most important in cell division. This knowledge could be used in the future in the development of cancer drugs”.Cancer cellsThousands of copies of cancer cells are created during cell division. New research into the APC/C may eventually put a stop to this”!  “The new study is a major step forward in our understanding of cell division. When the process goes awry it is a critical difference that separates cancer cells from their healthy counterparts. Understanding exactly how cancer cells divide inappropriately is crucial to the discovery of innovative cancer treatments to improve outcomes for cancer patients”. Full Story: Structure of protein vital to cancer development is mapped

I’m not afraid of death…….. staying alive is much harder! (Craig R. Becker)

Craig Becker

The New Denver Men’s Club

Blog: https://newdenvermensclub.wordpress.com/ “Men Fighting Cancer To Win”

 

 

 

(6) New Excellent Articles on potential Prostate Cancer Breakthroughs!

Hi Guys,

These articles are worth reading on new and potential PCa breakthroughs dealing with attacking the PCa cells, Parental diagnosis,  5-ARIs and risk for high-grade prostate cancer,  New diagnostic treatments, New nanoparticle created for cancer therapy and Targeting ‘sleeper agent’ cells in bones of prostate cancer patients.  The more we know, the better our fight!

1)  CBD Prostate Cancer Research: Non-THC Cannabinoids Inhibit Prostate Carcinoma Growth in Vitro and in Vivo

Posted by Pub Med – National Institutes of Health on June 17, 2014

“Cannabidiol (CBD) significantly inhibited cell viability. Other compounds became effective in cells deprived of serum for 24 h. Several BDS were more potent than the pure compounds in the presence of serum. CBD-BDS (i.p.) potentiated the effects of bicalutamide and docetaxel against LNCaP and DU-145 xenograft tumours and, given alone, reduced LNCaP xenograft size”. Full Story: Non-THC Cannabinoids Inhibit Prostate Carcinoma Growth

2)  Parental diagnosis and familial risk for prostate cancer: an 78-year analysis

 

(4 ) Excellent Articles on Prostate Cancer Potential Breakthroughs!

 

Hi Guys,

Current studies at Dana-Farber Cancer Institute and the Eastern Co-operative Oncology Group has proven from clinical trials that Chemo given before hormone blockage lives at least one year longer than chemo given after tumors become resistant to hormone blockage!  Article #2 states that patients who received external beam radiation therapy, they found these patients were estimated to be 70 percent more likely to be diagnosed with a rectal cancer and 40 percent more likely for bladder cancer than the general public.  Article #3 states that a immunotherapeutic agent has a markedly positive effect in the treatment of patients who are resistant to conventional hormone treatments and chemotherapy.  Article #4 deals with a new biopsy method to identify aggressive PCa cancers.

 

1)  Men with metastatic prostate cancer may live longer with chemo first  ( 2 June 2014)

” Dana-Farber Cancer Institute and the Eastern Co-operative Oncology Group say the dramatic results are likely to change current standard practice, which has been routine since the 1950s.  In a clinical trial, men with newly diagnosed, metastatic, hormone-sensitive prostate cancer who received chemotherapy straight away alongside hormone-blocking therapy lived more than a year longer than men who followed the standard treatment – which is to wait until the tumors have become resistant to hormone therapy before receiving chemotherapy”.  Full Article Here: Men with metastatic prostate cancer may live longer

2)  Risk of secondary cancers increased following radiation for prostate cancer  (3 June 2014 )

“Among men treated for prostate cancer, those who received radiation therapy were more likely to develop bladder or rectal cancer, according to a new study from the University of Michigan Comprehensive Cancer Center.  As a whole, men diagnosed with prostate cancer were at a lower risk of developing a second cancer. But when researchers looked at patients who received external beam radiation therapy, they found these patients were estimated to be 70 percent more likely to be diagnosed with a rectal cancer and 40 percent more likely for bladder cancer than the general public”.  Full Story Here:  Risk of secondary cancers increased following radiation

3)  Immunotherapy for prostate cancer in sight (27 May 2014 )

“The immunotherapeutic agent Ipilumumab has been shown to have a markedly positive effect in the treatment of patients who are resistant to conventional hormone treatments and chemotherapy. These are the words of a core statement from a study, recently published in the highly respected journal The Lancet Oncology, which was set up based on collaboration between the world’s leading centres for the research and treatment of prostate cancer”.  Full Story Here:  Immunotherapy for prostate cancer in sight

4)  New biopsy method more accurately identifies men at low risk for prostate cancer  ( 21 May 2014 )

“UCLA researchers found that conventional “blind” biopsy failed to reveal the true extent of presumed low-risk prostate cancers, and that when targeted biopsy was used, more than a third of these men had more aggressive cancers than they thought. Their aggressive cancers were not detected by conventional blind biopsy using ultrasound alone, and the men were referred to UCLA’s active surveillance program thinking they were at no immediate risk”.  Full Story Here:  New biopsy method

We are all “buying time” in life.  Some of us get more and others pay more!!

Craig Becker

The New Denver Men’s Club

Blog: https://newdenvermensclub.wordpress.com/   “Men Fighting Cancer To Win”